Moses AC - Search Results

1

Parenteral pamidronate prevents thyroid hormone-induced bone loss in rats.

Rosen HN, Sullivan EK, Middlebrooks VL, Zeind AJ, Gundberg C, Dresner-Pollak R, Maitland LA, Hock JM, Moses AC, Greenspan SL. Rosen HN, et al. Among authors: moses ac. J Bone Miner Res. 1993 Oct;8(10):1255-61. doi: 10.1002/jbmr.5650081014. J Bone Miner Res. 1993. PMID: 8256663

2

Therapy with parenteral pamidronate prevents thyroid hormone-induced bone turnover in humans.

Rosen HN, Moses AC, Gundberg C, Kung VT, Seyedin SM, Chen T, Holick M, Greenspan SL. Rosen HN, et al. Among authors: moses ac. J Clin Endocrinol Metab. 1993 Sep;77(3):664-9. doi: 10.1210/jcem.77.3.8370687. J Clin Endocrinol Metab. 1993. PMID: 8370687 Clinical Trial.

3

Randomized trial of pamidronate in patients with thyroid cancer: bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate.

Rosen HN, Moses AC, Garber J, Ross DS, Lee SL, Ferguson L, Chen V, Lee K, Greenspan SL. Rosen HN, et al. Among authors: moses ac. J Clin Endocrinol Metab. 1998 Jul;83(7):2324-30. doi: 10.1210/jcem.83.7.4782. J Clin Endocrinol Metab. 1998. PMID: 9661603 Clinical Trial.

4

Treatment with growth hormone and IGF-I in growing rats increases bone mineral content but not bone mineral density.

Rosen HN, Chen V, Cittadini A, Greenspan SL, Douglas PS, Moses AC, Beamer WG. Rosen HN, et al. Among authors: moses ac. J Bone Miner Res. 1995 Sep;10(9):1352-8. doi: 10.1002/jbmr.5650100912. J Bone Miner Res. 1995. PMID: 7502707

5

Bone density is normal in male rats treated with finasteride.

Rosen HN, Tollin S, Balena R, Middlebrooks VL, Moses AC, Yamamoto M, Zeind AJ, Greenspan SL. Rosen HN, et al. Among authors: moses ac. Endocrinology. 1995 Apr;136(4):1381-7. doi: 10.1210/endo.136.4.7895648. Endocrinology. 1995. PMID: 7895648

6

Subregion analysis of the rat femur: a sensitive indicator of changes in bone density following treatment with thyroid hormone or bisphosphonates.

Rosen HN, Middlebrooks VL, Sullivan EK, Rosenblatt M, Maitland LA, Moses AC, Greenspan SL. Rosen HN, et al. Among authors: moses ac. Calcif Tissue Int. 1994 Sep;55(3):173-5. doi: 10.1007/BF00425871. Calcif Tissue Int. 1994. PMID: 7987729

7

Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover.

Rosen HN, Dresner-Pollak R, Moses AC, Rosenblatt M, Zeind AJ, Clemens JD, Greenspan SL. Rosen HN, et al. Among authors: moses ac. Calcif Tissue Int. 1994 Jan;54(1):26-9. doi: 10.1007/BF00316285. Calcif Tissue Int. 1994. PMID: 8118749 Clinical Trial.

8

Short-term hyperthyroidism has no effect on leptin levels in man.

Mantzoros CS, Rosen HN, Greenspan SL, Flier JS, Moses AC. Mantzoros CS, et al. Among authors: moses ac. J Clin Endocrinol Metab. 1997 Feb;82(2):497-9. doi: 10.1210/jcem.82.2.3741. J Clin Endocrinol Metab. 1997. PMID: 9024243

9

Utility of biochemical markers of bone turnover in the follow-up of patients treated with bisphosphonates.

Rosen HN, Moses AC, Garber J, Ross DS, Lee SL, Greenspan SL. Rosen HN, et al. Among authors: moses ac. Calcif Tissue Int. 1998 Nov;63(5):363-8. doi: 10.1007/s002239900541. Calcif Tissue Int. 1998. PMID: 9799818 Clinical Trial.

10

Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy.

Rosen HN, Moses AC, Garber J, Iloputaife ID, Ross DS, Lee SL, Greenspan SL. Rosen HN, et al. Among authors: moses ac. Calcif Tissue Int. 2000 Feb;66(2):100-3. doi: 10.1007/pl00005830. Calcif Tissue Int. 2000. PMID: 10652955 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

145 results

Search Page

Filters